The Nile LM SIR sirolimus eluting intracoronary stent system will be indicated for the treatment of patients with pathological de novo coronary artery lesions located on left main bifurcation site.
The Nile LM SIR is a dedicated Left Main sirolimus eluting stent for distal Left Main lesions using an abluminal coating with a biodegradable polymer matrix. The drug is entirely eluted after 9 months with no residual polymer, completing conversion to bare metal stent.
Minvasys quality system is ISO 9001 and ISO 13485 certified, hence giving full support to its international partners for local market authorizations. Minvasys devices comply with the requirements of the European Medical Devices Directive 93/42/CEE.
Minvasys
7, rue du Fossé Blanc - 92230 Gennevilliers - France
Tel : +33 (0) 1 47 90 70 30
Fax : +33 (0) 1 47 91 05 85
info@minvasys.com
